We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+6.43%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$163M
AUM Growth
-$7.99M
Cap. Flow
-$11.8M
Cap. Flow %
-7.25%
Top 10 Hldgs %
72.59%
Holding
47
New
13
Increased
7
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$10.6M
2
MDT icon
Medtronic
MDT
+$9.96M
3
CVS icon
CVS Health
CVS
+$5.93M
4
QDEL icon
QuidelOrtho
QDEL
+$5.22M
5
SRCL
Stericycle Inc
SRCL
+$4.64M

Top Sells

Rank Stock Value
1
SPNC
Spectranetics Corp
SPNC
+$10.2M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.55M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$6.18M
4
BKD icon
Brookdale Senior Living
BKD
+$4.78M
5
LNTH icon
Lantheus
LNTH
+$4.48M

Sector Composition

Rank Sector Weight
1 Healthcare 92.51%
2 Industrials 6.36%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
$21M 12.85%
1,475,000
+225,000
+18% +$2.91M
NVCR icon
2
NovoCure
NVCR
$1.73B
$14.8M 9.04%
743,554
-161,446
-18% -$3.17M
NKTR icon
3
Nektar Therapeutics
NKTR
$2.39B
$13.2M 8.08%
36,667
-2,666
-7% -$834K
MDT icon
4
Medtronic
MDT
$109B
$12.8M 7.86%
165,000
+120,000
+267% +$9.96M
CORI
5
DELISTED
Corium International, Inc.
CORI
$10.5M 6.44%
950,000
-25,000
-3% -$221K
GILD icon
6
Gilead Sciences
GILD
$162B
$10.1M 6.2%
125,000
-10,000
-7% -$765K
PCRX icon
7
Pacira BioSciences
PCRX
$1.04B
$9.39M 5.75%
250,000
+35,000
+16% +$1.41M
LH icon
8
Labcorp
LH
$25B
$9.06M 5.55%
69,840
-9,312
-12% -$1.24M
NUVA
9
DELISTED
NuVasive, Inc.
NUVA
$8.87M 5.43%
+160,000
New +$10.6M
SRCL
10
DELISTED
Stericycle Inc
SRCL
$8.81M 5.39%
123,000
+63,000
+105% +$4.64M
QDEL icon
11
QuidelOrtho
QDEL
$1.14B
$6.58M 4.03%
+150,000
New +$5.22M
STE icon
12
Steris
STE
$22.3B
$6.19M 3.79%
70,000
-15,000
-18% -$1.27M
CVS icon
13
CVS Health
CVS
$133B
$6.1M 3.73%
+75,000
New +$5.93M
HIND
14
Vyome Holdings
HIND
$14.9M
– –
0
– –
CORV
15
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$3.73M 2.28%
1,750,000
-50,000
-3% -$170K
XRAY icon
16
Dentsply Sirona
XRAY
$2.68B
$2.99M 1.83%
50,000
-27,000
-35% -$1.61M
LNTH icon
17
Lantheus
LNTH
$6.49B
$2.31M 1.42%
130,000
-255,000
-66% -$4.48M
ATRC icon
18
AtriCure
ATRC
$1.92B
$2.24M 1.37%
+100,000
New +$2.26M
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.19M 1.34%
775,000
+150,000
+24% +$405K
RCM
20
DELISTED
R1 RCM Inc. Common Stock
RCM
$1.58M 0.97%
425,000
+175,000
+70% +$592K
STRM
21
DELISTED
Streamline Health Solutions
STRM
$1.54M 0.94%
69,778
-6,089
-8% -$110K
EVH icon
22
Evolent Health
EVH
$348M
$1.33M 0.82%
+75,000
New +$1.55M
SIEN
23
DELISTED
Sientra, Inc.
SIEN
$924K 0.57%
+6,000
New +$704K
ESRX
24
CALL
DELISTED
Express Scripts Holding Company
ESRX
$510K 0.31%
+1,000
New +$62.1K
HCA icon
25
CALL
HCA Healthcare
HCA
$87.2B
$454K 0.28%
+1,121
New +$90.2K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2017 Portfolio in Review

As of Q3 2017, Tamarack Advisers held 47 positions worth $163M, down 4.7% from $171M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Tamarack Advisers withdrew a net $11.8M in Q3 2017, closing 15 positions and reducing 10 holdings. Its most notable exit was Spectranetics Corp, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 95% a quarter earlier, followed by Industrials and Consumer Discretionary.

Against the trend, Tamarack Advisers opened a new position in NuVasive, Inc. worth $8.87M.

  • Tamarack Advisers's largest Q3 2017 buy was NuVasive, Inc.: 160,000 shares worth $8.87M.
  • Tamarack Advisers added most to Medtronic in Q3 2017, an estimated $9.96M increase.
  • Tamarack Advisers's biggest Q3 2017 reduction was Lantheus, cutting an estimated $4.48M.
  • Tamarack Advisers fully exited Spectranetics Corp in Q3 2017, selling an estimated $10.2M.
  • Tamarack Advisers's ten largest holdings make up 73% of its $163M portfolio in Q3 2017.
  • Tamarack Advisers opened 13 new positions and closed 15 in Q3 2017.
  • Tamarack Advisers's portfolio value fell 4.7% quarter-over-quarter to $163M.

Based on Tamarack Advisers's 13F filing for Q3 2017, filed 13 Nov 2017.